Hoping so. Been invested quite a while and just really interested in what prm are developing and bringing to healthcare
Out by now in prior years….waiting…..
Good spot. “Enquiries no later t11 April”.
29th February. Hoping for some kind of business update alongside….perhaps.
I don’t believe we will get the “way forward” RNS tonight, though no doubt the company and Prevail have a number of scenarios predrafted. I expect the wordsmithing will result in a Monday morning release which will resolve the obvious market query of how this gets funded forward. Personally not selling a bean.
Indeed, as had he1 we have an inflection point approaching. Still in here for the longer term development myself
Not sure about 30 but with progress made in all businesses…. Least happy with Bell…..should sit over 20.
Trading update expected end of January or first week of February. should include update on new facility.
Theres a Donald Hamilton of catalyst associates lp hedge fund but other than seeing his name linked to life sciences over a decade ago I have zero beyond speculation. Probably entirely unrelated.
Anyone know anything about The 3%RNS yesterday?
Question in my mind is whether Abingdon are effectively Scale up partners for Innovate Uk…..
I cannot find any evidence of a link. However, both companies were recipients in the 2018 Innovate Uk funding round, at a time when Abingdon were working on mastitis in cows. I see this now from Folium “ we are also developing tests for other bacteria such as Enterococcus, Clostridium and E.coli. And while poultry production is the first step on the ladder, there are numerous applications in animal farming and across the food industry for a test that is quick, simple, and accurate”. I think there may well be a collaboration. But no evidence .
This will be the next stage “ OBD is in the process of obtaining ISO15189 certification for a clinical lab within its Oxford, UK laboratory. Once certified, expected early in 2024, precision medicine tests, like EpiSwitch PSE, will be run there - shortening the overall turnaround time for results.” from September RNS. Wish I had insight on the process or eyes on the ground in Oxford… but I don’t….. so we wait.
Brief words with Sav director but thin piece by Caroline Bailey on 4
Remains a private company. Non traded.
Time will come, and I think soon. For the moment the spotlight is on OBD….
Absolutely right re Vulpes. Newbies should look up Vulpes life sciences and both Stephen and brother Martin Diggle. There is an impressive track record of identifying and developping businesses.
Agreed re finance and both good partnerships and excellent reputation. Was wondering about speed of rollout and any other steps ….this re Cirt “ A unique CPT PLA reimbursement code for the test has been available for use by US payors since October 2022.” wondering about reimbursement Code requirements for this test?
Obviously delighted with the initial price movement but I think there are information gaps that will put some off. A few thoughts….if you look on HL re OBD the last news you see is “losses widen”. I go back though to the May RNS for half year numbers which showed good revenue growth already and the comment “ We continue to focus commercially on growing CiRT sales and establishing the revenue engine while working diligently to launch the PSE clinical test before the end of 2023." So I think updated numbers which we probably wont have for a few months will give a much greater feeling of stability. This is not just a company with a breakthrough discovery that will fold due to finance. Turning to the US, an accredited lab is up and running, unsure if there is a need for a reimbursement code to be in place? Then on to the UK lab and NHS /private usage…. But I think that is for next year. Thoughts around first two areas especially welcome.
Suffice to say that with this one coming good, and Scancell and Proteome not far off Vulpes are shortly going to be rolling in it. Wonder where they go next. Would like to see Chronos Therapeutics go public but prob like recent Oxford spinouts will go to US….